Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders.
Eryn L WerryFiona M BrightOlivier PiguetLars M IttnerGlenda M HallidayJohn R HodgesMatthew C KiernanClement T LoyJillian June KrilMichael KassiouPublished in: International journal of molecular sciences (2019)
Neuroinflammation is an inflammatory response in the brain and spinal cord, which can involve the activation of microglia and astrocytes. It is a common feature of many central nervous system disorders, including a range of neurodegenerative disorders. An overlap between activated microglia, pro-inflammatory cytokines and translocator protein (TSPO) ligand binding was shown in early animal studies of neurodegeneration. These findings have been translated in clinical studies, where increases in TSPO positron emission tomography (PET) signal occur in disease-relevant areas across a broad spectrum of neurodegenerative diseases. While this supports the use of TSPO PET as a biomarker to monitor response in clinical trials of novel neurodegenerative therapeutics, the clinical utility of current TSPO PET radioligands has been hampered by the lack of high affinity binding to a prevalent form of polymorphic TSPO (A147T) compared to wild type TSPO. This review details recent developments in exploration of ligand-sensitivity to A147T TSPO that have yielded ligands with improved clinical utility. In addition to developing a non-discriminating TSPO ligand, the final frontier of TSPO biomarker research requires developing an understanding of the cellular and functional interpretation of the TSPO PET signal. Recent insights resulting from single cell analysis of microglial phenotypes are reviewed.
Keyphrases
- pet imaging
- positron emission tomography
- inflammatory response
- computed tomography
- lipopolysaccharide induced
- clinical trial
- spinal cord
- single cell
- neuropathic pain
- traumatic brain injury
- machine learning
- pet ct
- wild type
- spinal cord injury
- randomized controlled trial
- rna seq
- multiple sclerosis
- white matter
- amino acid
- open label
- double blind
- placebo controlled
- phase iii